Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

23.75
-0.1300-0.54%
Post-market: 23.60-0.1500-0.63%16:20 EDT
Volume:212.76K
Turnover:5.07M
Market Cap:697.79M
PE:-4.96
High:24.13
Open:23.65
Low:23.51
Close:23.88
Loading ...

AnaptysBio Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

AnaptysBio price target raised to $52 from $36 at Guggenheim

TIPRANKS
·
03 Mar

AnaptysBio Inc : Guggenheim Raises Target Price to $52 From $36

THOMSON REUTERS
·
03 Mar

An Expert Method to Overcome a Turbulent Stock Market

InvestorPlace
·
01 Mar

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

AnaptysBio Q4 2024 GAAP EPS $(0.72) Beats $(1.62) Estimate, Sales $43.113 Miss $7.767M Estimate

Benzinga
·
28 Feb

AnaptysBio Q4 Operating Expenses USD 52.783 Million

THOMSON REUTERS
·
28 Feb

Anaptys Announces Participation in March Investor Conferences

GlobeNewswire
·
28 Feb

Press Release: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
28 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
13 Feb

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

Zacks
·
13 Feb

AnaptysBio price target raised to $22 from $19 at H.C. Wainwright

TIPRANKS
·
13 Feb

BUZZ-AnaptysBio climbs on arthritis drug trial data

Reuters
·
12 Feb

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

TIPRANKS
·
12 Feb

AnaptysBio Shares Surge 37% After Mid-Stage Rheumatoid Arthritis Trial Meets Primary Goal

Dow Jones
·
12 Feb

AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise

MT Newswires Live
·
12 Feb

BRIEF-Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial

Reuters
·
12 Feb

AnaptysBio Inc - Rosinilimab Safe and Well Tolerated With Similar Adverse Event Rates VS Placebo

THOMSON REUTERS
·
12 Feb

AnaptysBio Inc - Rosinilimab Achieves Statistical Significance on Key Secondary Endpoints at Week 12

THOMSON REUTERS
·
12 Feb